Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-984923 · 1 trial · 1 indication
Total plasma concentration of caffeine as determined by pharmacokinetic modeling
Total plasma concentration of BMS-984923 as determined by pharmacokinetic modeling
plasma concentration of BMS-984923 as determined by pharmacokinetic modeling
| Arm | Type | Description |
|---|---|---|
| 50 mg Active once daily | EXPERIMENTAL | - |
| 50 mg Active twice daily | EXPERIMENTAL | - |
| 100 mg Active twice daily | EXPERIMENTAL | - |
| Reference drugs cocktail | EXPERIMENTAL | midazolam, caffeine and dextromethorphan will be administered orally |
| Name | Type | Description |
|---|---|---|
| BMS-984923 | DRUG | oral capsules once or twice daily |
| Midazolam | DRUG | midazolam, oral, 2mg administered before study drug and after study drug |
| Caffeine | DRUG | Caffeine, oral, 100mg administered before study drug and after study drug |
| dextromethorphan | DRUG | dextromethorphan, oral, 30mg administered before study drug and after study drug |
Inclusion Criteria: * Men or women between the ages of 18 and 50 years, inclusive. * No history of cognitive impairment. * Capable of providing written informed consent and willing to comply with all study requirements and procedures. * Female participants, if of childbearing potential, must be non...
BMS-984923 is an investigational small molecule being studied for its potential to alter the systemic exposure of three orally administered probe substrates. It is currently in a Phase 1 clinical trial focused on drug-drug interactions (DDI) in healthy volunteers in the United States.
BMS-984923 is being developed by cbdMD, Inc., a company traded under the ticker YCBD. The drug is currently in Phase 1 clinical development for drug-drug interaction studies.
BMS-984923 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 trial is active but not recruiting participants.
BMS-984923 is being evaluated in one Phase 1 clinical trial, NCT06632990, titled "A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates." The trial is active but not recruiting, with an enrollment of 36 healthy volunteers in the United States.
No alternative names for BMS-984923 have been disclosed. The drug is identified solely by its code name BMS-984923 in the available clinical trial information.